NASDAQ:BFRA
Delisted
Biofrontera AG Stock News
$2.67
+0 (+0%)
At Close: Aug 17, 2022
Biofrontera AG announces the closing of the capital raise with gross proceeds of EUR 24.7 million
09:20am, Friday, 26'th Feb 2021
Leverkusen, Germany, Feb. 26, 2021 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (“Biofrontera” or the “Company”), an international biopharmaceutical company
Biofrontera Raises $8.9M Via Equity Offering
07:17am, Wednesday, 24'th Feb 2021
Biofrontera AG (NASDAQ: BFRA) priced an underwritten public offering of around 1.3 million ADS at $6.68 per ADS, raising gross proceeds of approximately $8.9 million. The offer price represents a
Biofrontera AG Announces Pricing of US$8.9 Million Firm Commitment Public Offering of American Depositary Shares
07:54pm, Tuesday, 23'rd Feb 2021
NOT FOR DISTRIBUTION OUTSIDE THE UNITED STATES
Biofrontera announces preliminary revenue figures for the full year 2020
09:35am, Friday, 08'th Jan 2021
Leverkusen, Germany, Jan. 08, 2021 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today reported prel
Cologne Higher Regional Court grants approval of capital increase
11:45am, Thursday, 07'th Jan 2021
Leverkusen, Germany, Jan. 07, 2021 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, announces that the
Biofrontera enters into a license and supply agreement with Galenica AB for the marketing of Ameluz® in Scandinavia
09:10am, Monday, 07'th Dec 2020
Leverkusen, Germany, Dec. 07, 2020 (GLOBE NEWSWIRE) -- Biofrontera Pharma GmbH, a wholly owned subsidiary of Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F), and Galenica AB, Malmö, Swed
Biofrontera AG (BFRA) CEO Hermann Lübbert on Q2 2020 Results - Earnings Call Transcript
10:46am, Thursday, 27'th Aug 2020
Biofrontera AG (NASDAQ:BFRA) Q2 2020 Earnings Conference Call August 27, 2020 08:00 AM ET Company Participants Pamela Keck - Head, Investor Relations Hermann Lübbert - Chief Executive Officer Thomas
Biofrontera announces conference call to be held on August 27, 2020 to discuss half-year 2020 financial results
08:30am, Wednesday, 19'th Aug 2020
Leverkusen, Germany, Aug. 19, 2020 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, will be releasing i
Capital measure oversubscribed: Placement of the 1.00 % qualified subordinated mandatory convertible bond 2020/2021
09:00am, Tuesday, 18'th Aug 2020
Leverkusen, Germany, Aug. 18, 2020 (GLOBE NEWSWIRE) -- In a press release dated July 27, 2020, Biofrontera AG (shares of Biofrontera AG ISIN: DE0006046113) announced the issuance of up to 2,638,150 1.
Result of the subscription of the 1.00 % qualified subordinated mandatory convertible bond 2020/2021
08:50pm, Thursday, 13'th Aug 2020
Leverkusen, Germany, Aug. 13, 2020 (GLOBE NEWSWIRE) -- Biofrontera AG (shares of Biofrontera AG ISIN: DE0006046113) announced on July 27, 2020 the issuance of the 1.00% qualified subordinated mandator
Biofrontera AG announces subscription price for 1.00 % qualified subordinated mandatory convertible bond 2020/2021
02:00pm, Monday, 10'th Aug 2020
Leverkusen, Aug. 10, 2020 (GLOBE NEWSWIRE) -- The Executive Board of Biofrontera AG (shares of Biofrontera AG ISIN: DE0006046113) has decided on 27 July 2020, with the approval of the Supervisory Boar
Biofrontera AG resolves to issue qualified subordinated mandatory convertible bonds
05:15pm, Monday, 27'th Jul 2020
Leverkusen, Germany, July 27, 2020 (GLOBE NEWSWIRE) -- The Management Board of Biofrontera AG (NASDAQ ticker symbol: BFRA, ISIN: DE0006046113), today resolved, with the approval of the Supervisory Boa
Supervisory Board of Biofrontera AG renews Management Board appointment
12:30pm, Thursday, 23'rd Jul 2020
Leverkusen, Germany, July 23, 2020 (GLOBE NEWSWIRE) -- The Supervisory Board of Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F), an international biopharmaceutical company, today announce
Biofrontera reports preliminary unaudited sales revenue for the first six months of 2020
10:08am, Tuesday, 14'th Jul 2020
Leverkusen, Germany, July 14, 2020 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company” or the “Biofrontera-Group”), an international biopharmaceutic
Biofrontera confirms financing need
12:30pm, Tuesday, 30'th Jun 2020
Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today confirmed the financing requirements to maintain ongoing business op
